Steven G. Kaminsky Scout Program
The Steven G. Kaminsky Scout Program is dedicated to proactively accelerating research. Your gift funds this proprietary program to test new or repurposed compounds for potential use in Rett syndrome.
Accelerating Research
The Steve. G. Kaminsky Scout Program provides a rigorous platform for drug companies to screen new or repurposed compounds that they believe might be useful in treating Rett syndrome. This program allows industry to more quickly evaluate their drug’s potential, saving them significant time and money.
Since its inception in 2013, 27 companies have used the program to test over 33 compounds. Multiple compounds screened through the program have moved through to clinical trials, both in the United States and abroad.
Dedicated to Dr. Kaminsky
In 2013, IRSF launched the Scout Program under the direction of Chief Science Officer, Steven G. Kaminsky, PhD to use the RTT mouse model to screen discovery drugs. In 2019, the Scout Program was renamed to honor Dr. Kaminsky in his pursuit of treatments and a cure for Rett syndrome. IRSF thanks Dr. Kaminsky as well as those who have helped build the program:
- Dr. John McCall, PharMac, LLC
- Dr. Garry Smith, Fox Chase Chemical Diversity Center, Inc.
- Dr. Stephen Ginsberg, Nathan Kline Institute, New York University
- Dr. Aleksandra Djukic, Montefiore Medical Center, Albert Einstein College of Medicine
- Dr. Raj Ratan, Burke Medical Research Institute, Cornell University
- Dr. Marcie Glicksman, Brigham and Women’s Hospital, Harvard University
- Dr. Dani Brunner, EarlySignals
Support the Cause.
There are many ways to join the fight against Rett syndrome. You can raise awareness, get involved in grassroots advocacy, or explore other impactful opportunities. Every action matters. Together, we can transform the lives of those living with Rett.